I recently came across some exciting news about a new treatment for hormone receptor-positive breast cancer called Alpelisib. This groundbreaking drug, when used in combination with endocrine therapy, has shown significant improvements in progression-free survival for patients. It specifically targets PIK3CA-mutated tumors, which are found in about 40% of HR-positive breast cancers. The FDA has approved Alpelisib, and it's expected to become a new standard of care in treating this type of cancer. I'm really hopeful that this innovative treatment will make a huge difference in the lives of many breast cancer patients.